ArticleInternational journal of clinical and experimental medicine2015
miRNA-101 inhibits ovarian cancer cells proliferation and invasion by down-regulating expression of SOCS-2.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Comparative Analysis of Tumor-Associated microRNAs and Tetraspanines from Exosomes of Plasma and Ascitic Fluids of Ovarian Cancer Patients.International journal of molecular sciences · 2022Article
- miR-3648 promotes lung adenocarcinoma-genesis by inhibiting SOCS2 (suppressor of cytokine signaling 2).Bioengineered · 2022Article
- Interaction Between microRNAs and Myeloid-Derived Suppressor Cells in Tumor Microenvironment.Frontiers in immunology · 2022Review
- Knockdown of Myeloid Cell Leukemia-1 by MicroRNA-101 Increases Sensitivity of A549 Lung Cancer Cells to Etoposide.Iranian journal of medical sciences · 2021Article
- lncRNA-Xist/miR-101-3p/KLF6/C/EBPα axis promotes TAM polarization to regulate cancer cell proliferation and migration.Molecular therapy. Nucleic acids · 2021Article
- MicroRNA-126 exerts antitumor functions in ovarian cancer by targeting EGFL7 and affecting epithelial-to-mesenchymal transition and ERK/MAPK signaling pathway.Oncology letters · 2020Article
- Article
- Gene Therapy with MiRNA-Mediated Targeting of Mcl-1 Promotes the Sensitivity of Non-Small Cell Lung Cancer Cells to Treatment with ABT-737.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Wnt/β-catenin signalling in ovarian cancer: Insights into its hyperactivation and function in tumorigenesis.Journal of ovarian research · 2019Review
- MicroRNA-375 inhibits esophageal squamous cell carcinoma proliferation through direct targeting of SP1.Experimental and therapeutic medicine · 2019Article
- Circulating non-coding RNAs in recurrent and metastatic ovarian cancer.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- miRNA-101-5p inhibits the growth and aggressiveness of NSCLC cells through targeting CXCL6.OncoTargets and therapy · 2019Article
- Prognostic implications of decreased microRNA-101-3p expression in patients with non-small cell lung cancer.Oncology letters · 2018Article
- MicroRNA‑665 suppresses the growth and migration of ovarian cancer cells by targeting HOXA10.Molecular medicine reports · 2018Article
- LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression.Molecular cancer · 2018Article
- MicroRNA-152 inhibits ovarian cancer cell proliferation and migration and may infer improved outcomes in ovarian cancer through targeting FOXP1.Experimental and therapeutic medicine · 2018Article
- Diagnostic and prognostic implications of serum miR-101 in osteosarcoma.Cancer biomarkers : section A of Disease markers · 2018Article
- MicroRNA-384 inhibits proliferation migration and invasion of glioma by targeting at CDC42.OncoTargets and therapy · 2018Article
- Downregulation of serum miR-101 is associated with worse prognosis in non-small cell lung cancer.International journal of clinical and experimental pathology · 2018Article
- MicroRNAs in gynecological cancers: Small molecules with big implications.Cancer letters · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the expression of miRNA-101 in normal and malignant ovarian tissues and cells as well as its impact on the proliferation and invasion of human ovarian cancer H08910 and SKOV3 cell lines.
methodsReal time polymerase chain reaction (RT-PCR) was employed to detect the miR-101 and SOCS-2 expression in 20 separate ovarian cancer tissues and para-carcinoma tissues, human ovarian cancer cells (H08910 and SKOV3) and normal human ovarian epithelial cells (HUM-CELL-0088). After H08910 and SKOV3 ovarian cancer cells were respectively transfected with miR-NC (H08910/NC and SKOV3/NC) and miR-101 (H08910/miR-101 and SKOV3/miR-101), Western Blot was employed to detect the SOCS-2 expression in transfected cells. CCK-8 and clone formation and Transwell assays were employed to determine the proliferation and invasion ability of wild type and transfected ovarian cancer cells.
resultsThe expression of miR-101 in ovarian cancer tissues and cells was significantly lower than that in para-carcinoma tissues (t=19.12, P=0.002) and normal human ovarian epithelial cells (HUM-CELL-0088) (F=14.37, P=0.000), respectively. In contrast, the SOCS-2 expression in ovarian cancer tissues and cells was significantly higher than that in para-carcinoma tissues (t=25.03, P=0.000) and HUM-CELL-0088 cells (F=14.9, P=0.000) by Western Blotting analysis, respectively. Compared with wild type and empty vector transfected cells, the expression of SOCS-2 was significantly decreased in miR-101 transfected H08910 (t=10.9, P=0.001) and SKOV3 cells (t=21.03, P=0.000). The results of CCK-8, clone formation and Transwell assays revealed that the proliferation and invasion ability of ovarian cancer cells was markedly inhibited by the transfection of miR-101.
conclusionMiR-101 was validated to be reduced and SOCS-2 expression increased in ovarian cancer tissues and cells. The over expression of miR-101 can remarkably reduce the in vitro proliferation and invasion ability of ovarian cancer cells through the down-regulation of SOCS-2.
Indexed as
Identifiers
26884939PMC4723784W2416242586What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.